Mupadolimab

立即咨询

Mupadolimab

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

2451856-97-4

CPI-006

Mupadolimab (CPI-006) 是一种 IgG1κ 人源化的 FcγR 结合缺陷抗CD73单抗，激活 CD73^POSB 细胞。

生物活性

Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73monoclonal antibody (mAb) that activatesCD73^POSB cells^[1].

IC₅₀& Target

CD73^[1]

体外研究
(In Vitro)

Mupadolimab induces the increased expression of markers associated with B cell maturation and antigen presentation, morphologic transformation to plasmablasts, and increased secretion of IgM and IgG^[1].

体内研究
(In Vivo)

Mupadolimab (10 mg/kg; i.p.; daily for 15 days) stimulates antigen specific humoral immunity in SARS-CoV-2 infected NSG-SGM3 mice^[1].

Animal Model:	NSG-SGM3 mice, immunized with an emulsion of 50 μg full length spike protein from SARS-CoV-2 and Freund’s Incomplete Adjuvant subcutaneously on both the left and right flank (25 μg/side)^[1]
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection, daily for 15 days
Result:	Mice treated with the drug made antibodies to the immunizing TS protein; but not to the control nucleocapsid SARS-CoV-2 viral protein.

Clinical Trial

性状

Liquid

CAS 号

2451856-97-4

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.